Delving into the Latest Updates on Alliance Medical Products, Inc. with Synapse

Overview

Tags

Neoplasms

Urogenital Diseases

Shared antigen vaccine

DNA vaccine

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Neoplasms	1
Immune System Diseases	1
Infectious Diseases	1

Top 5 Drug Type	Count

Shared antigen vaccine	1
DNA vaccine	1

Top 5 Target	Count

E6 x HPV E7	1

[Translation] A randomized, double-blind, placebo-controlled Phase III clinical study to evaluate the efficacy and safety of intramuscular VGX-3100 combined with electroporation using CELLECTRA™ 5PSP for the treatment of HPV-16 and/or HPV-18 related high-grade squamous intraepithelial lesions (HSIL) of the cervix

验证VGX-3100相比安慰剂在成年女性中宫颈HSIL组织病理学转归伴随HPV-16和/或HPV-18病毒学清除复合终点的有效性

[Translation]

To verify the efficacy of VGX-3100 compared with placebo in adult women on the composite endpoint of cervical HSIL histopathological outcome and HPV-16 and/or HPV-18 virological clearance

Start Date09 Nov 2021

Sponsor / Collaborator

Inovio Pharmaceuticals, Inc.

[+2]

CTR20210163

/ CompletedPhase 3

评价SHR8028滴眼液治疗干眼病的有效性和安全性-多中心、随机、双盲、赋形剂平行对照Ⅲ期临床试验

[Translation] Evaluation of the efficacy and safety of SHR8028 eye drops in the treatment of dry eye disease: a multicenter, randomized, double-blind, vehicle-controlled phase III clinical trial

以赋形剂为对照，评价SHR8028滴眼液治疗干眼病的有效性、安全性和耐受性。

[Translation]

Using excipients as a control, the efficacy, safety, and tolerability of SHR8028 eye drops in the treatment of dry eye disease were evaluated.

Start Date04 Mar 2021

Sponsor / Collaborator

Alliance Medical Products, Inc.

[+2]

CTR20210154

/ CompletedPhase 3

评价 SHR8058 滴眼液治疗睑板腺功能障碍相关干眼病的有效性和安全性-多中心、随机、双盲、盐溶液平行对照 III 期临床试验

[Translation] Evaluation of the efficacy and safety of SHR8058 eye drops in the treatment of dry eye associated with meibomian gland dysfunction: a multicenter, randomized, double-blind, saline-controlled phase III clinical trial

以0.6％氯化钠溶液作对照，评价 QID 给药方案下 SHR8058 滴眼液治疗睑板腺功能障碍（MGD）相关干眼病的症状和体征的有效性。

[Translation]

To evaluate the efficacy of SHR8058 eye drops in the treatment of symptoms and signs of dry eye disease associated with meibomian gland dysfunction (MGD) under a QID dosing regimen, compared with 0.6% sodium chloride solution.

Start Date03 Feb 2021

Sponsor / Collaborator

Alliance Medical Products, Inc.

[+2]

100 Clinical Results associated with Alliance Medical Products, Inc.

Login to view more data

0 Patents (Medical) associated with Alliance Medical Products, Inc.

Login to view more data

100 Deals associated with Alliance Medical Products, Inc.

Login to view more data

100 Translational Medicine associated with Alliance Medical Products, Inc.

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 19 Apr 2025

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Phase 3

1

3

Other

Login to view more data

Current Projects

Drug(Targets)	Indications	Global Highest Phase

Bizalimogene ralaplasmid ( E6 x HPV E7 )	Squamous Intraepithelial Lesions of the Cervix More	Phase 3
Perfluorohexyloctane ( Lipid )	Meibomian Gland Dysfunction More	Pending
Cyclosporine ( CaN )	Xerophthalmia More	Pending
IONIS-GCGRRx ( GCGR )	Diabetes Mellitus, Type 2 More	Pending